Early research (Phase 1)Study completedNCT02226861
What this trial is testing
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Acute Myelogenous Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)+2 more
National Heart, Lung, and Blood Institute (NHLBI) 24